Table 3.
N | HR (95% CI) | p value | |
---|---|---|---|
aGVHD | |||
BMI | |||
Normal | 290 | 1.00 | – |
UW | 20 | 1.11 (0.56-2.21) | 0.76 |
OW | 287 | 1.03 (0.78-1.35) | 0.85 |
OB | 301 | 1.15 (0.89-1.50) | 0.29 |
Other covariates | |||
Continuous age | 898 | 1.00 (0.99-1.00) | 0.37 |
Malignancy | |||
Non-malignant | 53 | 1.00 | – |
Malignant | 845 | 1.73 (0.82-3.68) | 0.15 |
Relatedness | |||
Related | 447 | 1.00 | – |
Unrelated | 451 | 1.88 (1.50-2.35) | <0.001 |
Transplant type | |||
PB | 763 | 1.00 | – |
BM | 135 | 0.66 (0.44-0.99) | 0.04 |
HLA match | |||
Matched | 762 | 1.00 | – |
Mismatched | 136 | 1.69 (1.30-2.17) | <0.001 |
Conditioning intensity | |||
Myeloablative | 551 | 1.00 | – |
Reduced | 347 | 1.19 (0.94-1.49) | 0.14 |
Year of transplant | |||
2004-2008 | 492 | 1.00 | – |
2008-2013 | 406 | 0.76 (0.61-0.95) | 0.02 |
cGVHD | |||
BMI | |||
Normal | 290 | 1.00 | – |
UW | 20 | 0.99 (0.46-2.12) | 0.98 |
OW | 287 | 1.07 (0.83-1.38) | 0.60 |
OB | 301 | 1.21 (0.94-1.55) | 0.14 |
Other covariates | |||
Continuous age | 898 | 1.00 (0.99-1.01) | 0.69 |
Malignancy | |||
Non-malignant | 53 | 1.00 | – |
Malignant | 845 | 1.29 (0.72-2.31) | 0.38 |
Relatedness | |||
Related | 447 | 1.00 | – |
Unrelated | 451 | 1.13 (0.92-1.39) | 0.23 |
Transplant type | |||
PB | 763 | 1.00 | – |
BM | 135 | 0.91 (0.61-1.36) | 0.65 |
HLA match | |||
Matched | 762 | 1.00 | – |
Mismatched | 136 | 0.95 (0.73-1.25) | 0.73 |
Conditioning intensity | |||
Myeloablative | 551 | 1.00 | – |
Reduced | 347 | 1.02 (0.82-1.27) | 0.82 |
Year of transplant | |||
2004-2008 | 492 | 1.00 | – |
2008-2013 | 406 | 0.96 (0.79-1.17) | 0.70 |
NRM | |||
BMI | |||
Normal | 290 | 1.00 | – |
UW | 20 | 1.74 (0.76-4.01) | 0.19 |
OW | 287 | 0.95 (0.65-1.37) | 0.77 |
OB | 301 | 1.43 (1.02-2.01) | 0.04 |
Other covariates | |||
Continuous age | 898 | 1.01 (1.00-1.02) | 0.18 |
Malignancy | |||
Non-malignant | 53 | 1.00 | – |
Malignant | 845 | 0.37 (0.10-1.33) | 0.13 |
Relatedness | |||
Related | 447 | 1.00 | – |
Unrelated | 451 | 2.20 (1.65-2.94) | <0.001 |
Transplant type | |||
PB | 763 | 1.00 | – |
BM | 135 | 0.23 (0.09-0.58) | 0.002 |
HLA match | |||
Matched | 762 | 1.00 | – |
Mismatched | 136 | 1.59 (1.16-2.22) | 0.004 |
Conditioning intensity | |||
Myeloablative | 551 | 1.00 | – |
Reduced | 347 | 1.02 (0.76-1.35) | 0.91 |
Year of transplant | |||
2004-2008 | 492 | 1.00 | – |
2008-2013 | 406 | 0.79 (0.60-1.05) | 0.10 |
Relapse | |||
BMI | |||
Normal | 290 | 1.00 | – |
UW | 20 | 0.70 (0.32-1.50) | 0.36 |
OW | 287 | 0.79 (0.61-1.03) | 0.08 |
OB | 301 | 0.65 (0.49-0.86) | 0.002 |
Other covariates | |||
Continuous age | 898 | 1.00 (1.00-1.01) | 0.36 |
Malignancy | |||
Non-malignant | 53 | 1.00 | – |
Malignant | 845 | 26.50 (3.49-201.02) | 0.002 |
Relatedness | |||
Related | 447 | 1.00 | – |
Unrelated | 451 | 0.61 (0.48-0.77) | <0.001 |
Transplant type | |||
PB | 763 | 1.00 | – |
BM | 135 | 1.09 (0.72-1.66) | 0.68 |
HLA match | |||
Matched | 762 | 1.00 | – |
Mismatched | 136 | 0.83 (0.60-1.18) | 0.29 |
Conditioning intensity | |||
Myeloablative | 551 | 1.00 | – |
Reduced | 347 | 0.90 (0.69-1.16) | 0.42 |
Year of transplant | |||
2004-2008 | 492 | 1.00 | – |
2008-2013 | 406 | 0.76 (0.60-0.95) | 0.02 |
OS | |||
BMI | |||
Normal | 290 | 1.00 | – |
UW | 20 | 1.02 (0.54-1.95) | 0.95 |
OW | 287 | 0.85 (0.68-1.07) | 0.17 |
OB | 301 | 0.93 (0.75-1.16) | 0.55 |
Other covariates | |||
Continuous age | 898 | 1.01 (1.00-1.02) | 0.003 |
Malignancy | |||
Non-malignant | 53 | 1.00 | – |
Malignant | 845 | 2.05 (0.92, 4.58) | 0.08 |
Relatedness | |||
Related | 447 | 1.00 | – |
Unrelated | 451 | 1.24 (1.03-1.49) | 0.02 |
Transplant type | |||
PB | 763 | 1.00 | – |
BM | 135 | 0.56 (0.38-0.82) | 0.003 |
HLA match | |||
Matched | 762 | 1.00 | – |
Mismatched | 136 | 1.41 (1.12-1.79) | 0.003 |
Conditioning intensity | |||
Myeloablative | 551 | 1.00 | – |
Reduced | 347 | 0.89 (0.74-1.09) | 0.24 |
Year of transplant | |||
2004-2008 | 492 | 1.00 | – |
2008-2013 | 406 | 0.78 (0.65-0.94) | 0.01 |